ADK and epilepsy: Manipulated WJMSCs by Adeno, AAV, non-integrated lentiviral, CRISPR/Cas9 and RNA transferinstead of lentivirus, might be a suitable source in cell-based and ex vivo gene therapy of epilepsy and could beevaluated for ADK knockdown, in vivo.